300298 三诺生物
已收盘 10-13 15:00:00
资讯
新帖
简况
三诺生物(300298)10月9日主力资金净买入966.92万元
证券之星 · 10-12 09:09
三诺生物(300298)10月9日主力资金净买入966.92万元
三诺生物(300298)披露回购公司股份进展公告,10月09日股价上涨4.25%
证券之星 · 10-09
三诺生物(300298)披露回购公司股份进展公告,10月09日股价上涨4.25%
股市必读:三诺生物(300298)9月28日董秘有最新回复
证券之星 · 09-29
股市必读:三诺生物(300298)9月28日董秘有最新回复
三诺生物:当前全球主流 CGM 产品均以血糖单指标监测为主
证券之星 · 09-28
三诺生物:当前全球主流 CGM 产品均以血糖单指标监测为主
“药二代”密集走向台前,大多拥有海外名校背景,将如何接好“转型”这一棒?
红星资本局 · 09-22
“药二代”密集走向台前,大多拥有海外名校背景,将如何接好“转型”这一棒?
三诺生物涨5.18%,国金证券一个月前给出“买入”评级
证券之星 · 09-21
三诺生物涨5.18%,国金证券一个月前给出“买入”评级
研报掘金丨华源证券:维持三诺生物“买入”评级,盈利能力持续改善
格隆汇 · 09-16
研报掘金丨华源证券:维持三诺生物“买入”评级,盈利能力持续改善
三诺生物(300298)披露取得医疗器械注册证暨注册变更公告,9月8日股价上涨0.7%
证券之星 · 09-08
三诺生物(300298)披露取得医疗器械注册证暨注册变更公告,9月8日股价上涨0.7%
三诺生物:二代CGM暂未向美国FDA正式提交注册申请
证券之星 · 09-04
三诺生物:二代CGM暂未向美国FDA正式提交注册申请
股市必读:三诺生物新发布《关于回购公司股份的进展公告》
证券之星 · 09-03
股市必读:三诺生物新发布《关于回购公司股份的进展公告》
三诺生物(300298)披露回购公司股份进展公告,9月1日股价上涨0.75%
证券之星 · 09-01
三诺生物(300298)披露回购公司股份进展公告,9月1日股价上涨0.75%
三诺生物:2026年上半年净利润同比增长22.52%
证券之星 · 08-21
三诺生物:2026年上半年净利润同比增长22.52%
三诺生物:已布局臂筒式、臂式、腕式三大类血压计产品
证券之星 · 08-18
三诺生物:已布局臂筒式、臂式、腕式三大类血压计产品
三诺生物:即时检测POCT产品实现营业收入4.31亿元
证券之星 · 08-18
三诺生物:即时检测POCT产品实现营业收入4.31亿元
三诺生物:截至2026年7月31日已累计回购股份7,847,644股
证券之星 · 08-17
三诺生物:截至2026年7月31日已累计回购股份7,847,644股
股市必读:三诺生物(300298)8月14日董秘有最新回复
证券之星 · 08-17
股市必读:三诺生物(300298)8月14日董秘有最新回复
三诺生物:产品安全方面,公司已获得ISO 9001、ISO 13485、MDSAP、IVDR、MDR等多项国际权威质量管理体系认证
证券之星 · 08-14
三诺生物:产品安全方面,公司已获得ISO 9001、ISO 13485、MDSAP、IVDR、MDR等多项国际权威质量管理体系认证
研报掘金丨浙商证券:维持三诺生物“增持”评级,境内业务发展强劲
格隆汇 · 08-06
研报掘金丨浙商证券:维持三诺生物“增持”评级,境内业务发展强劲
股市必读:三诺生物新发布《2026年半年度报告摘要》
证券之星 · 08-05
股市必读:三诺生物新发布《2026年半年度报告摘要》
三诺生物(300298)6月30日股东户数2.31万户,较上期减少8.68%
证券之星 · 08-04
三诺生物(300298)6月30日股东户数2.31万户,较上期减少8.68%
公司概况
公司名称:
三诺生物传感股份有限公司
所属行业:
专用设备制造业
上市日期:
2012-03-19
主营业务:
三诺生物传感股份有限公司的主营业务是血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计等生产和销售。公司的主要产品是家用医疗产品、等级医院专业产品、基层医疗专业产品、糖尿病医疗健康服务。公司作为血糖监测领域领先企业,相继获得国内外权威机构的高度认可和荣誉。荣获“国家企业技术中心”“国家工程研究中心”“国家技术创新示范企业”“国家知识产权优势企业”“国家科技进步二等奖”“国家绿色工厂”和“制造业单项冠军企业”等资质。
发行价格:
29.00
{"stockData":{"symbol":"300298","market":"SZ","secType":"STK","nameCN":"三诺生物","latestPrice":16.4,"timestamp":1791875010000,"preClose":16.76,"halted":0,"volume":4758140,"delay":0,"changeRate":-0.0215,"floatShares":448000000,"shares":557000000,"eps":0.2395,"marketStatus":"已收盘","change":-0.36,"latestTime":"10-13 15:00:00","open":16.64,"high":16.64,"low":16.25,"amount":78215900,"amplitude":0.0233,"askPrice":16.4,"askSize":172,"bidPrice":16.38,"bidSize":1,"shortable":0,"etf":0,"ttmEps":0.2395,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791941400000},"marketStatusCode":5,"adr":0,"adjPreClose":16.76,"symbolType":"stock","openAndCloseTimeList":[[1791855000000,1791862200000],[1791867600000,1791874800000]],"highLimit":18.44,"lowLimit":15.08,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":556845893,"isCdr":false,"pbRate":3.16,"roa":"--","peRate":68.475992,"roe":"7.02%","epsLYR":0.1685,"committee":-0.34139,"marketValue":9132000000,"turnoverRate":0.0106,"status":1,"floatMarketCap":7347000000},"requestUrl":"/m/hq/s/300298/wiki","defaultTab":"wiki","newsList":[{"id":"2674476798","title":"三诺生物(300298)10月9日主力资金净买入966.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674476798","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674476798?lang=zh_cn&edition=full","pubTime":"2026-10-12 09:09","pubTimestamp":1791767362,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月9日收盘,三诺生物报收于16.68元,上涨4.25%,换手率1.95%,成交量8.73万手,成交额1.43亿元。近5日资金流向一览见下表:三诺生物融资融券信息显示,融资方面,当日融资买入1023.29万元,融资偿还754.76万元,融资净买入268.53万元。三诺生物主营业务:血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计等生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200002945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0102","300298","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674734830","title":"三诺生物(300298)披露回购公司股份进展公告,10月09日股价上涨4.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674734830","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674734830?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:39","pubTimestamp":1791538755,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘,三诺生物报收于16.68元,较前一交易日上涨4.25%,最新总市值为92.88亿元。该股当日开盘15.94元,最高16.75元,最低15.94元,成交额达1.43亿元,换手率为1.95%。公司于2026年10月8日发布《关于回购公司股份的进展公告》。公告显示,三诺生物传感股份有限公司于2026年3月27日召开第六届董事会第三次会议,于2026年4月13日召开临时股东会,审议通过回购股份方案。回购进展符合既定方案及相关法律法规要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900027831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0102","BK0114","300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671322252","title":"股市必读:三诺生物(300298)9月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2671322252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671322252?lang=zh_cn&edition=full","pubTime":"2026-09-29 02:19","pubTimestamp":1790619547,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘,三诺生物报收于16.19元,上涨0.25%,换手率0.83%,成交量3.7万手,成交额6024.77万元。董秘最新回复投资者: 你好,董秘。一台机器就搞定董秘: 您好!当前全球主流 CGM 产品均以血糖单指标监测为主。公司现阶段聚焦于持续葡萄糖监测产品,技术平台具备向更多代谢指标延伸的潜力,将结合技术成熟度与市场实际需求审慎布局相关研发。当日关注点交易信息汇总:9月28日主力资金净流入94.08万元,占总成交额1.56%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900002132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300298","BK0102","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670628319","title":"三诺生物:当前全球主流 CGM 产品均以血糖单指标监测为主","url":"https://stock-news.laohu8.com/highlight/detail?id=2670628319","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670628319?lang=zh_cn&edition=full","pubTime":"2026-09-28 11:42","pubTimestamp":1790566923,"startTime":"0","endTime":"0","summary":"证券之星消息,三诺生物(300298)09月28日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,董秘。请问一下,什么时候CGM可以像BGM一样,又测血糖又能测尿酸。一台机器就搞定三诺生物回复:您好!当前全球主流 CGM 产品均以血糖单指标监测为主。公司现阶段聚焦于持续葡萄糖监测(CGM)产品,技术平台具备向更多代谢指标延伸的潜力,将结合技术成熟度与市场实际需求审慎布局相关研发。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800010780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0114","BK0251","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669234144","title":"“药二代”密集走向台前,大多拥有海外名校背景,将如何接好“转型”这一棒?","url":"https://stock-news.laohu8.com/highlight/detail?id=2669234144","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669234144?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:16","pubTimestamp":1790079360,"startTime":"0","endTime":"0","summary":"红星资本局注意到,“药二代”们正密集走向台前。与“创一代”不同的是,他们大多拥有海外名校背景,进入核心管理层的方式也各不相同。今年以来,还有多位“药二代”走向台前。多家药企处于业务转型期二代接棒或面临考验值得一提的是,近期迎来“药二代”上台的上市公司,多数处于业务转型期。“药二代”走向前台,企业如何完成转型,仍有待时间验证。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-09-22/doc-inistexc1956967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0314109678.HKD","LU0315179316.USD","LU1152091754.HKD","LU1226287529.USD","LU0072913022.USD","LU1008478684.HKD","LU1960683339.HKD","IE00BZ08YS42.EUR","LU1226287875.USD","688166","300453","LU1226287792.SGD","LU0326950275.SGD","IE00B031HY20.USD","BK0188","000513","600380","BK0114","LU1813983027.USD","LU1993786604.SGD","BK0102","BK0028","HK0000165453.HKD","SG9999004220.SGD","LU0140636845.USD","BK1191","IE00BZ08YR35.GBP","IE0008368742.USD","IE00BZ08YT58.USD","BK0239","LU1226288170.HKD","KURE","LU1807302812.USD","LU1226288253.USD","LU0880133367.SGD","BK0046","BK0251","LU0067412154.USD","BK0187","01093","LU1328277881.USD","LU2039709279.SGD","300298","BK1521","LU0501845795.SGD","BK0077","LU1152091168.USD","LU1951186391.HKD","IE0008369823.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669592811","title":"三诺生物涨5.18%,国金证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669592811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669592811?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:46","pubTimestamp":1789980373,"startTime":"0","endTime":"0","summary":"今日三诺生物涨5.18%,收盘报16.44元。2026年8月4日,国金证券研究员甘坛焕,何冠洲发布了对三诺生物的研报《境内业务高增长,创新转型稳步推进》,该研报对三诺生物给出“买入”评级。研报中预计公司 2026-2028 年归母净利润分别为 4.05、4.99、6.09 亿元,同比+338%、+23%、+22%,现价对应 PE 为 23、18、15 倍,维持“买入”评级。三诺生物个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100021012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605518","title":"研报掘金丨华源证券:维持三诺生物“买入”评级,盈利能力持续改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605518","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667605518?lang=zh_cn&edition=full","pubTime":"2026-09-16 15:53","pubTimestamp":1789545223,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0114","161027","BK0102","BK0251","300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665216283","title":"三诺生物(300298)披露取得医疗器械注册证暨注册变更公告,9月8日股价上涨0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665216283","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665216283?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:59","pubTimestamp":1788861565,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘,三诺生物报收于15.9元,较前一交易日上涨0.7%,最新总市值为88.54亿元。该股当日开盘15.77元,最高15.99元,最低15.73元,成交额达4737.37万元,换手率为0.67%。三诺生物传感股份有限公司于2026年9月8日披露《关于取得医疗器械注册证暨医疗器械注册变更的公告》。公告显示,公司近日获得国家药品监督管理局和湖南省药品监督管理局颁发的多项医疗器械注册证及变更文件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","159883","BK1100","BK1583","BK0102","09996","BK1574","300298","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333068","title":"三诺生物:二代CGM暂未向美国FDA正式提交注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333068","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333068?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:45","pubTimestamp":1788515107,"startTime":"0","endTime":"0","summary":"证券之星消息,三诺生物09月04日在投资者关系平台上答复投资者关心的问题。董秘,市场预期2026年内提交美国FDA注册,但公司明确表示为正式提交。公司二代 CGM 暂未向美国 FDA 正式提交注册申请,系公司基于一代CGM产品注册经验总结、产品上市策略,临床研究方案持续完善、全球专利风险综合评估及商业化策略统筹等多方面因素审慎决策的结果,并非由单一因素影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400031908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300298","BK0251","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664845036","title":"股市必读:三诺生物新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664845036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664845036?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:31","pubTimestamp":1788373869,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年8月31日,三诺生物已回购股份9,176,644股,占总股本1.65%,成交总额1.49亿元。公司公告汇总关于回购公司股份的进展公告三诺生物传感股份有限公司于2026年3月27日召开第六届董事会第三次会议,2026年4月13日召开临时股东大会,审议通过回购股份方案,拟使用自有或自筹资金以集中竞价方式回购股份,用于注销并减少注册资本,回购金额不低于15,000万元且不超过30,000万元,价格不超25.00元/股,期限为股东会审议通过起12个月内。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300298","BK0102","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664369850","title":"三诺生物(300298)披露回购公司股份进展公告,9月1日股价上涨0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664369850","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664369850?lang=zh_cn&edition=full","pubTime":"2026-09-01 23:05","pubTimestamp":1788275121,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,三诺生物报收于16.08元,较前一交易日上涨0.75%,最新总市值为89.54亿元。该股当日开盘16.04元,最高16.21元,最低15.97元,成交额达5405.74万元,换手率为0.75%。近日,三诺生物传感股份有限公司披露《关于回购公司股份的进展公告》。截至2026年8月31日,已回购股份9,176,644股,占总股本1.65%,最高成交价17.10元/股,最低14.19元/股,成交总额149,024,338.74元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0114","BK0102","300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222264","title":"三诺生物:2026年上半年净利润同比增长22.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222264","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661222264?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:30","pubTimestamp":1787308228,"startTime":"0","endTime":"0","summary":"公司上半年净利润实现了22.52%的增长,但经营现金流却同比下降了13.12%。同时,应收账款增速追平了营收增速。2026 年上半年,公司实现营业收入 25.37 亿元,同比增长 12.08%;归属于上市公司股东的净利润 2.21 亿元,同比增长 22.52%;扣除非经常性损益的净利润 2.10 亿元,同比增长 32.87%,利润增速高于营收增速,主要得益于产品结构优化、毛利率提升及内部成本管控成效显现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660618194","title":"三诺生物:已布局臂筒式、臂式、腕式三大类血压计产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2660618194","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660618194?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:45","pubTimestamp":1787049916,"startTime":"0","endTime":"0","summary":"证券之星消息,三诺生物(300298)08月18日在投资者关系平台上答复投资者关心的问题。投资者提问:你好!董秘,最近鱼跃出了一块手表式血压计,咱们有类似产品研发吗?三诺生物回复:您好!公司在血压监测领域已布局臂筒式、臂式、腕式三大类血压计产品,并推出了具备物联网功能的智能血压计。公司近期已上市房颤臂筒式血压计S21等新品,持续提升血压监测的临床价值与用户体验。公司目前暂未推出手表式血压计,将基于该类产品可及的测量准确性和市场需求进行审慎评估与规划布局。感谢您对公司的关注!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800035377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0251","BK0102","BK0114"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660469031","title":"三诺生物:即时检测POCT产品实现营业收入4.31亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660469031","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660469031?lang=zh_cn&edition=full","pubTime":"2026-08-18 18:39","pubTimestamp":1787049554,"startTime":"0","endTime":"0","summary":"证券之星消息,三诺生物08月18日在投资者关系平台上答复投资者关心的问题。近年来公司积极拓展糖尿病及相关慢病多元化监测产品和服务,搭建起以血糖检测为基础、慢病相关指标检测为核心的产品矩阵,持续推进血糖、血脂、尿酸、糖化血红蛋白等多指标联测产品研发与市场推广。2026年上半年,公司即时检测POCT产品实现营业收入4.31亿元,同比增长10.56%,整体保持稳健增长态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800035324.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480177","title":"三诺生物:截至2026年7月31日已累计回购股份7,847,644股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660480177?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:51","pubTimestamp":1786971071,"startTime":"0","endTime":"0","summary":"证券之星消息,三诺生物08月17日在投资者关系平台上答复投资者关心的问题。截至 2026 年 7月 31 日,公司已累计回购股份7,847,644股,占公司总股本的 1.41%,成交总金额127,424,720.74 元。公司将结合二级市场股价波动、市场交易机会及公司阶段性资金统筹节奏,在符合法律法规及窗口期规定的前提下择机推进回购,并严格按照信息披露要求及时履行披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700032665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300298","BK0114","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660217004","title":"股市必读:三诺生物(300298)8月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660217004","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660217004?lang=zh_cn&edition=full","pubTime":"2026-08-17 03:00","pubTimestamp":1786906845,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘,三诺生物报收于16.4元,下跌0.91%,换手率1.34%,成交量6.0万手,成交额9900.65万元。董秘最新回复投资者: 请问三诺生物还有可信度吗?如您有进一步的疑问,欢迎通过公司投资者关系热线与我们联系。当日关注点交易信息汇总:8月14日主力资金净流出156.59万元,占总成交额1.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700001116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0102","BK0114","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659179241","title":"三诺生物:产品安全方面,公司已获得ISO 9001、ISO 13485、MDSAP、IVDR、MDR等多项国际权威质量管理体系认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2659179241","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659179241?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:24","pubTimestamp":1786699454,"startTime":"0","endTime":"0","summary":"公司始终高度重视产品质量与用户信任:1、产品安全方面,公司已获得ISO 9001、ISO 13485、MDSAP、IVDR、MDR等多项国际权威质量管理体系认证,在全球主要市场均通过相关质量合规审核与产品认证,全方位确保产品的持续安全和有效,目前未发现系统性风险;2、信息披露方面,公司严格按照《公司法》《证券法》《深圳证券交易所创业板股票上市规则》等法律法规的要求,真实、准确地履行信息披露义务,确保所有投资者平等获取公司信息。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0114","BK0102","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657688756","title":"研报掘金丨浙商证券:维持三诺生物“增持”评级,境内业务发展强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2657688756","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657688756?lang=zh_cn&edition=full","pubTime":"2026-08-06 15:23","pubTimestamp":1786001027,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0276","BK0114","BK0102","601878","BK0251","300298"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563547","title":"股市必读:三诺生物新发布《2026年半年度报告摘要》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657563547?lang=zh_cn&edition=full","pubTime":"2026-08-05 01:48","pubTimestamp":1785865697,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,三诺生物报收于16.18元,下跌2.24%,换手率2.74%,成交量12.27万手,成交额1.97亿元。公司公告汇总:三诺生物决定不向下修正“三诺转债”转股价格,并承诺2026年8月4日至12月20日期间不再修正。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500001810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0114","BK0251","BK0102"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656312745","title":"三诺生物(300298)6月30日股东户数2.31万户,较上期减少8.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656312745","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656312745?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:51","pubTimestamp":1785837081,"startTime":"0","endTime":"0","summary":"证券之星消息,近日三诺生物披露,截至2026年6月30日公司股东户数为2.31万户,较3月31日减少2194.0户,减幅为8.68%。在医疗器械行业个股中,三诺生物股东户数高于行业平均水平,截至6月30日,医疗器械行业平均股东户数为2.14万户。从股价来看,2026年3月31日至2026年6月30日,三诺生物区间跌幅为12.1%,在此期间股东户数减少2194.0户,减幅为8.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400030037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","BK0114","BK0102","300298"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791903954088,"stockEarnings":[{"period":"1week","weight":0.0282},{"period":"1month","weight":0.1041},{"period":"3month","weight":0.1012},{"period":"6month","weight":0.0455},{"period":"1year","weight":-0.1637},{"period":"ytd","weight":-0.0205}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三诺生物传感股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"23087人(较上一季度减少8.68%)","perCapita":"19404股","listingDate":"2012-03-19","address":"湖南省长沙市岳麓区高新技术产业开发区谷苑路265号;湖南省长沙市岳麓区青山西路11号","registeredCapital":"55684万元","survey":" 三诺生物传感股份有限公司的主营业务是血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计等生产和销售。公司的主要产品是家用医疗产品、等级医院专业产品、基层医疗专业产品、糖尿病医疗健康服务。公司作为血糖监测领域领先企业,相继获得国内外权威机构的高度认可和荣誉。荣获“国家企业技术中心”“国家工程研究中心”“国家技术创新示范企业”“国家知识产权优势企业”“国家科技进步二等奖”“国家绿色工厂”和“制造业单项冠军企业”等资质。","listedPrice":29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三诺生物(300298)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三诺生物(300298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三诺生物,300298,三诺生物股票,三诺生物股票老虎,三诺生物股票老虎国际,三诺生物行情,三诺生物股票行情,三诺生物股价,三诺生物股市,三诺生物股票价格,三诺生物股票交易,三诺生物股票购买,三诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三诺生物(300298)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三诺生物(300298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}